Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 5/20 | 0.63 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.63 |
| ▸ | GRIA3 | P42263 | 5/20 | 0.63 |
| ▸ | GRIA4 | P48058 | 5/20 | 0.63 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.50 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.50 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.50 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.50 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8682533 | 0.85 | GRIA1 (0.47) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8682827 | 0.81 | GRIA1 (0.47) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7739865 | 0.79 | GRIA1 (0.61) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8609904 | 0.78 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8684601 | 0.78 | KDM4E (0.37) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8684587 | 0.77 | GRIK1 (0.64) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7740361 | 0.71 | GRIA1 (0.54) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL6602457 | 0.71 | GRIA1 (0.60) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL7740364 | 0.69 | GRIA1 (0.48) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8689719 | 0.69 | GRIA1 (0.66) | GRIA1GRIA2GRIA3GRIA4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5776949-A | USEFUL AS INHIBITORS OF THE PATHOLOGICAL PHENOMENA LINKED TO HYPERACTIVATION OF THE NEUROTRANSMISSION PATHWAYS BY THE EXCITATORY AMINO ACIDS; ADMINISTERING TO TREAT CEREBRAL VASCULAR ACCIDENT, EPILEPSY, ISCHEMIA AND CONVULSIONS | ADIR ET COMPAGNIE (FR) | 1998-07-07 | — | — | US | disclosed |